Charles River Laboratories International Inc. (CRL) Company Profile & Statistics

Charles River Laboratories International Inc.
CRL
(NYSE)
Closed
187.74
-9.16 (-4.65%)
in:usd•As of: Nov 15, 2024 15:59 UTC -5
Pre Market:0+0.00 (0.00%)
Open
194.53
High
195.75
Low
183.67

About Charles River Laboratories International Inc.

CEO

James C. Foster

Headquarters

251 ballardvale street

wilmington, ma 01887, united states

Auditor

PricewaterhouseCoopers LLP

Employees

21,800

Share Holders

Website

www.criver.com

Industry

miscellaneous commercial services

Sector

commercial services

Company Overview

Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support.

Charles River Laboratories International Inc. Statistics

Valuation Measures

Market Capitalization ²	9.60B
Enterprise Value	11.83B
Enterprise Value/EBITDA (ttm)	13.25
Price to Earnings Ratio (ttm)	18.55
Price to Book (mrq)	2.53
Price to Sales (ttm)	2.36
Price to Cash (ytd)	11.17

Profitability

Gross Margin (ttm)	34.93%
Operating Margin (ttm)	12.99%
Profit Margin (ttm)	10.84%
Return on Equity (ttm)	14.29%
Return on Invested Capital (ttm)	7.25%
Return on Assets (ttm)	6.53%

Income Statement

Revenue (ttm)	4.08B
Revenue Per Share (ttm)	78.98
Gross Profit (ttm)	1.42B
EBITDA (ttm)³	892.88M
Net Income Avi to Common (ttm)	441.51M
Diluted EPS (ttm)	7.99

Share Statistics

Beta (5Y Monthly)	1.38
52-Week Change	-1.46%
S&P500 52-Week Change	29.10%
S&P500 Member	Yes
Stock Optionable	Yes
Total Shares Outstanding ¹	51.63M
Dividend Yield	0.00%
Float ⁴	50.47M
% Held by Insiders	1.30%
% Held by Institutions	98.91%

Balance Sheet

Total Cash (mrq)	179.21M
Total Cash Per Share (mrq)	3.47
Total Debt (mrq)	2.41B
Total Debt/Equity (mrq)	64.65%
Current Ratio (mrq)	1.58%
Quick Ratio (mrq)	1.14%
Book Value Per Share (mrq)	72.21

Cash Flow

Operating Cash Flow Per Share (ytd)	6.24
Free Cash Flow (ytd)	204.79M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Charles River Laboratories International Inc.

Trade With A Regulated Broker